文献速递产科母胎医学

子宫托联合黄体酮预防宫颈短孕妇早产:一项随机对照试验

Pessary Plus Progesterone to Prevent Preterm Birth in Women With Short Cervixes: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2022-01-01

该多中心开放标签随机对照试验纳入宫颈长度≤30 mm的无症状单胎或双胎孕妇,比较子宫托联合阴道黄体酮与单用阴道黄体酮(200 mg/日)的效果。主要复合结局新生儿死亡与疾病发生率两组无显著差异(19.2% vs 20.9%,aRR 0.88,95%CI 0.69-1.12)。子宫托组阴道分泌物、疼痛及阴道出血均更多。

要点

  • 子宫托联合黄体酮未降低主要复合新生儿结局风险(aRR 0.88,95%CI 0.69-1.12)。
  • 子宫托组34周前分娩率低于单用黄体酮组(aRR 0.66,95%CI 0.47-0.93)。
  • 子宫托组阴道分泌物、疼痛及阴道出血发生率均显著高于单用黄体酮组。

核心结论

  • 在无症状宫颈短的孕妇中,子宫托联合黄体酮与单用黄体酮相比未降低新生儿疾病或死亡发生率。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在17个围产中心进行。
  • 纳入无症状单胎或双胎孕妇,妊娠18 0/7至22 6/7周宫颈长度≤30 mm,随机分为子宫托联合阴道黄体酮组或单用阴道黄体酮组(200 mg/日)。
  • 治疗从随机化至妊娠36周或分娩,按意向治疗分析。
  • 2015年7月9日至2019年3月29日筛查8,168名孕妇,475名随机至子宫托组,461名至单用黄体酮组。

主要发现

  • 主要复合围产结局发生率子宫托组19.2%(89/463)vs 单用黄体酮组20.9%(91/436),aRR 0.88,95%CI 0.69-1.12。
  • 37周前分娩率子宫托组29.1% vs 单用黄体酮组31.4%,aRR 0.86,95%CI 0.72-1.04。
  • 34周前分娩率子宫托组9.9% vs 单用黄体酮组13.9%,aRR 0.66,95%CI 0.47-0.93。
  • 子宫托组阴道分泌物发生率51.6%(245/476)vs 单用黄体酮组25.4%(117/479),P<.001。
  • 子宫托组疼痛发生率33.1%(157/476)vs 单用黄体酮组24.1%(111/479),P=.002;阴道出血发生率9.7%(46/476)vs 4.8%(22/479),P=.004。

临床怎么用

  • 对于无症状宫颈短的孕妇,子宫托联合黄体酮与单用黄体酮相比未降低新生儿疾病或死亡发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the effectiveness of cervical pessary in addition to vaginal progesterone for the prevention of preterm birth in women with midpregnancy short cervixes. METHODS: We performed a multicenter, open-label, randomized controlled trial in 17 perinatal centers. Asymptomatic women with singleton or twin pregnancies and cervical lengths of 30 mm or less, measured at 18 0/7-22 6/7 weeks of gestation, were randomized to cervical pessary plus vaginal progesterone (pessary plus progesterone group) or vaginal progesterone only (progesterone-only group) (200 mg/day). Treatments were used from randomization to 36 weeks of gestation or delivery. The primary outcome was a composite of neonatal mortality and morbidity. Secondary outcomes were delivery before 37 weeks and before 34 weeks of gestation. Analysis was performed according to intention to treat. RESULTS: Between July 9, 2015, and March 29, 2019, 8,168 women were screened, of whom 475 were randomized to pessary and 461 to progesterone only. The composite perinatal outcome occurred in 19.2% (89/463) of the women in the pessary group compared with 20.9% (91/436) of the women in the progesterone-only group (adjusted risk ratio [aRR] 0.88, 95% CI 0.69-1.12). Delivery rates before 37 weeks of gestation were 29.1% compared with 31.4% (aRR 0.86, 95% CI 0.72-1.04); delivery rates before 34 weeks were 9.9% compared with 13.9% (aRR 0.66, 95% CI 0.47-0.93). Women in the pessary group had more vaginal discharge (51.6% [245/476] vs 25.4% [117/479] [P<.001]), pain (33.1% [157/476] vs 24.1% [111/479] [P=.002]), and vaginal bleeding (9.7% [46/476] vs 4.8% [22/479] [P=.004]). CONCLUSION: In asymptomatic women with short cervixes, the combination of pessary and progesterone did not decrease rates of neonatal morbidity or mortality when compared with progesterone only. CLINICAL TRIAL REGISTRATION: Brazilian Clinical Trial Registry (ReBec), UTN:U1111-1164-2636.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pacagnella RC, Silva TV, Cecatti JG, et al. Pessary Plus Progesterone to Prevent Preterm Birth in Women With Short Cervixes: A Randomized Controlled Trial. Obstet Gynecol. 2022. PMID: 34856583. doi:10.1097/AOG.0000000000004634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。